Data / Form D filings / General Oncology, Inc.
General Oncology, Inc.: Form D filings
General Oncology, Inc., a pharmaceuticals company in Newton, MA, filed 12 Form D notices with the SEC between 2015 and 2026. The latest, on April 23, 2026, reports $4.8 million sold of a $4.8 million offering to 37 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 57 Chapel Street, Third Floor, Newton, MA, 02458
- Phone
- (617) 468-4646
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1658021
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | New notice | $4,805,299 | $4,805,299 | 37 | Apr 15, 2026 | sec.gov | |
| Jul 2, 2025 | Amendment | $17,325,000 | $10,879,308 | $6,445,692 | 43 | Jun 25, 2019 | sec.gov |
| Jul 2, 2024 | Amendment | $11,250,000 | $7,203,721 | $4,046,279 | 35 | Jun 25, 2019 | sec.gov |
| Dec 21, 2023 | Amendment | $7,500,000 | $6,028,721 | $1,471,279 | 34 | Jun 25, 2019 | sec.gov |
| Dec 22, 2022 | Amendment | $7,500,000 | $3,203,721 | $4,296,279 | 31 | Jun 25, 2019 | sec.gov |
| Nov 10, 2022 | Amendment | $3,750,000 | $3,203,721 | $546,279 | 31 | Jun 25, 2019 | sec.gov |
| Nov 10, 2021 | Amendment | $3,750,000 | $2,305,000 | $1,445,000 | 29 | Jun 25, 2019 | sec.gov |
| Dec 23, 2020 | Amendment | $2,500,000 | $1,428,750 | $1,071,250 | 19 | Jun 25, 2019 | sec.gov |
| Jul 14, 2020 | Amendment | $1,250,000 | $730,000 | $520,000 | 12 | Jun 25, 2019 | sec.gov |
| Jul 9, 2019 | New notice | $1,250,000 | $445,000 | $805,000 | 8 | Jun 25, 2019 | sec.gov |
| Sep 5, 2017 | Amendment | $46,905,641 | $34,803,641 | $12,102,000 | 140 | Nov 2, 2015 | sec.gov |
| Nov 16, 2015 | New notice | $46,905,641 | $31,340,641 | $15,565,000 | 129 | Nov 2, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jeffrey Aaron Glazier | Executive Officer, Director | |
| Arnold Glazier | Executive Officer, Director | |
| Abid Ansari | Executive Officer | |
| Michael J. Petit | Director | |
| Barry Seeman | Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Apr 20, 2026 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what General Oncology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.